Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Acquisitions & Divestments (2023 - 2025)

Collegium Pharmaceutical (COLL) has 3 years of Change in Acquisitions & Divestments data on record, last reported at $19.8 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 24.2% year-over-year to $19.8 million; the TTM value through Dec 2025 reached $65.2 million, down 29.62%, while the annual FY2025 figure was $65.2 million, 29.62% down from the prior year.
  • Change in Acquisitions & Divestments reached $19.8 million in Q4 2025 per COLL's latest filing, up from $14.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $29.4 million in Q3 2024 and bottomed at $13.8 million in Q2 2025.
  • Average Change in Acquisitions & Divestments over 3 years is $19.3 million, with a median of $17.0 million recorded in 2025.
  • The widest YoY moves for Change in Acquisitions & Divestments: up 24.2% in 2025, down 50.49% in 2025.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $16.0 million in 2023, then fell by 0.15% to $16.0 million in 2024, then increased by 24.2% to $19.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $19.8 million in Q4 2025, $14.6 million in Q3 2025, and $13.8 million in Q2 2025.